Key facts
- This page summarizes Catherine M. Bonuccelli's Form 4 filing for IRulya Therapeutics Inc. (IRLA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Nov 2026, 16:10.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Beginning October 8, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Issuer's 2026 Equity Incentive Plan) with the Issuer as of each such vesting date.